# OnCo record cutaneous-scc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cutaneous-scc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cutaneous-scc" ;
  schema:name "Cutaneous squamous cell carcinoma"@en ;
  schema:alternateName "cSCC"@en, "Squamous Cell Carcinoma of the Skin"@en, "Squamous cell skin cancer"@en, "Squamous cell carcinoma of the skin"@en, "SCC of the skin"@en, "Keratinocyte carcinoma, squamous type"@en, "Cutaneous SCC"@en, "Epidermoid carcinoma of skin"@en ;
  schema:description "Cutaneous squamous cell carcinoma is a sun-related skin cancer with over a million US cases a year, almost all cured by removing them. The 2 to 5% that grow deep or spread respond to PD-1 immunotherapy (cemiplimab, pembrolizumab), which is now also given after surgery in high-risk cases; transplant recipients cannot safely receive it."@en ;
  schema:url <https://onco.cc/cancers/cutaneous-scc/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Squamous-cell_carcinoma_of_the_skin> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1465>, <https://doi.org/10.1056/NEJMoa2502449>, <https://www.cancer.gov/types/skin/patient/skin-treatment-pdq>, <https://doi.org/10.1016/S1470-2045(08)70178-5>, <https://doi.org/10.1001/jamadermatol.2013.2139>, <https://doi.org/10.1136/bmj.f6153>, <https://doi.org/10.1001/archderm.136.12.1524>, <https://doi.org/10.3390/cancers17243921>, <https://www.skinhealthinfo.org.uk/condition/squamous-cell-carcinomas/>, <https://www.skinhealthinfo.org.uk/condition/skin-cancer-in-organ-transplant-recipients/>, <https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/follow-up-appointments>, <https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/surgery/treatment-surgery-types>, <https://doi.org/10.1002/ijc.27765>, <https://doi.org/10.1001/jamadermatol.2016.4920>, <https://www.rcpath.org/resourceLibrary/g124datasetsquamous-pdf.html>, <https://www.cancerresearchuk.org/about-cancer/skin-cancer/types/squamous-cell-carcinoma>, <https://doi.org/10.1111/bjd.19621>, <https://www.rcpath.org/resourceLibrary/squamous-cell-tnm9.html>, <https://doi.org/10.1001/jamadermatol.2013.2456>, <https://doi.org/10.1200/jco.2012.48.5326>, <https://doi.org/10.1001/jamadermatol.2019.0032>, <https://doi.org/10.1001/jamadermatol.2017.3960>, <https://www.cancerresearchuk.org/about-cancer/skin-cancer/survival>, <https://doi.org/10.1093/bjd/ljad033>, <https://doi.org/10.1093/bjd/ljag315>, <https://doi.org/10.1002/ski2.61>, <https://www.nhs.uk/conditions/non-melanoma-skin-cancer/symptoms/> ;
  onco:tag "gap-fill", "skin" ;
  onco:related <https://onco.cc/cancers/basal-cell-carcinoma/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/bowens-disease/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/technologies/dermoscopy-ai/>, <https://onco.cc/technologies/oncolytic-virus/>, <https://onco.cc/technologies/black-salve-escharotics/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/psycho-oncology/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cosibelimab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/imiquimod/>, <https://onco.cc/drugs/aminolevulinic-acid/>, <https://onco.cc/drugs/acitretin/>, <https://onco.cc/drugs/nicotinamide/> ;
  onco:companies <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/sanofi/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/summit-therapeutics/>, <https://onco.cc/companies/replimune/>, <https://onco.cc/companies/rakuten-medical/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/perineural-invasion/>, <https://onco.cc/terms/second-primary-skin-cancer/>, <https://onco.cc/terms/sun-protection-after-skin-cancer/>, <https://onco.cc/terms/skin-cancer-after-organ-transplant/>, <https://onco.cc/terms/curettage-and-cautery/>, <https://onco.cc/terms/facial-scar-after-skin-cancer/>, <https://onco.cc/terms/skin-graft-and-flap-reconstruction/>, <https://onco.cc/pathways/field-cancerisation/>, <https://onco.cc/terms/keratinocyte-cancer/>, <https://onco.cc/terms/actinic-keratosis/>, <https://onco.cc/terms/cscc-subtype-and-grade/>, <https://onco.cc/terms/bwh-staging-cscc/>, <https://onco.cc/terms/tnm-skin-carcinoma/>, <https://onco.cc/terms/skin-cancer-high-risk-features/>, <https://onco.cc/terms/keratinocyte-cancer-counting/>, <https://onco.cc/terms/keratoacanthoma/>, <https://onco.cc/terms/inherited-skin-cancer-syndromes/>, <https://onco.cc/terms/carcinoma-in-situ/>, <https://onco.cc/terms/mohs-surgery/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/terms/radiotherapy-for-skin-cancer/>, <https://onco.cc/terms/surgical-margins-keratinocyte-cancer/> ;
  onco:trials <https://onco.cc/trials/nct06585410/>, <https://onco.cc/trials/empower-cscc-1/>, <https://onco.cc/trials/c-post/>, <https://onco.cc/trials/neoadjuvant-cemiplimab-cscc/>, <https://onco.cc/trials/trog-05-01/>, <https://onco.cc/trials/tumorapa/>, <https://onco.cc/trials/cemiplimab-kidney-transplant-cscc/>, <https://onco.cc/trials/mohs-versus-excision-facial-bcc/> ;
  onco:pipeline <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/cosibelimab/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/hmbd-001/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cosibelimab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/terms/perineural-invasion/>, <https://onco.cc/terms/wide-local-excision/>, <https://onco.cc/terms/mohs-surgery/>, <https://onco.cc/terms/curettage-and-cautery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/skin-cancer-after-organ-transplant/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/terms/second-primary-skin-cancer/>, <https://onco.cc/terms/perineural-invasion/>, <https://onco.cc/terms/sun-protection-after-skin-cancer/>, <https://onco.cc/terms/skin-cancer-after-organ-transplant/>, <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/pathways/field-cancerisation/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/trials/trog-05-01/>, <https://onco.cc/terms/radiotherapy-for-skin-cancer/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/terms/perineural-invasion/>, <https://onco.cc/trials/neoadjuvant-cemiplimab-cscc/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/surgical-margins-keratinocyte-cancer/>, <https://onco.cc/terms/skin-cancer-after-organ-transplant/>, <https://onco.cc/trials/tumorapa/>, <https://onco.cc/trials/cemiplimab-kidney-transplant-cscc/>, <https://onco.cc/drugs/acitretin/>, <https://onco.cc/drugs/nicotinamide/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cosibelimab/>, <https://onco.cc/trials/c-post/> .